Physician profile
David Telander
NPI 1528043023
$17,622.64
in general payments reported to CMS, 2019-2025
22 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 82% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $3,044 · 2021: $366 · 2022: $2,317 · 2023: $4,730 · 2024: $4,241 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,632 · Food and Beverage: $4,040 · Honoraria: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,631.75 |
| Food and Beverage | $4,040.25 |
| Honoraria | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $4,373.28 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $3,050.05 | 2022-2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $2,956.56 | 2023-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $2,128.58 | 2022-2025 | |
| Genentech USA, INC. | $1,148.00 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $1,051.58 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $711.58 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $462.21 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $323.47 | 2022-2025 | Acthar |
| Alcon Vision LLC | $252.35 | 2019-2021 | |
| Biogen, INC. | $201.15 | 2022-2023 | |
| Amgen INC. | $189.84 | 2024-2025 | Pavblu |
| Genentech, INC. | $179.91 | 2024-2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $174.45 | 2023-2025 | Xipere, Retisert, Visudyne |
| Coherus Oncology, INC. | $125.00 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $103.13 | 2025 | Iheezo, Triesence |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Ani Pharmaceuticals, INC. | $43.12 | 2025 | Purified Cortrophin Gel, Yutiq |
| Eyepoint US, INC. | $36.56 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.02 | 2019 | |
| Allergan, INC. | $20.04 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Telander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.